In a recent interview at the SNMMI conference, Krishna Patel, M.D., discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz and new research findings showing the agent’s increased sensitivity and specificity in diagnosing coronary artery disease in obese patients.
The use of single-photon emission computed tomography (SPECT)/computed tomography (CT) to monitor the effectiveness of Lu-177-PSMA (Pluvicto) in treating prostate cancer led to a greater than 50 percent decrease in prostate-specific antigen (PSA) level for 60 percent of patients in a new study, noted Andrew Nguyen, MBBS, FRACP, AANMS, in a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
Carch up on the top radiology content of the past week.
Employing a hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) model to assess predictive features of Alzheimer’s disease (AD), researchers noted a 100 percent sensitivity rate and a 93 percent sensitivity rate for distinguishing between AD and normal cognition, according to a study presented at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
In an interview at the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Jeremie Calais, M.D., MSc discussed promising research findings for the use of the positron emission tomography (PET) imaging agent 89ZR-DFO-girentuximab for diagnosing clear cell renal cell carcinoma.
New research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference suggests that neuroreceptor differences in reactions to visual food cues between obese people and normal-weight individuals may improve the understanding of underlying mechanisms that contribute to obesity.
In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D., Ph.D, F.A.C.R., discussed the potential impact of urinary activity with positron emission tomography (PET) radiopharmaceuticals, and new phase 3 study data that found low urinary activity with the use of the flotufolastat F 18 injectable agent in patients with prostate cancer.
Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.
A next-generation positron emission tomography/computed tomography (PET/CT) system, Biograph Vision.X, reportedly offers enhanced spatial resolution and a time of flight of 178 picoseconds.
The research, which garnered “Abstract of the Year” honors at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, demonstrates the potential of the targeted agent to significantly improve survival rates in AML.
The novel tracer improved both sensitivity and specificity in the study group, of which more than 50 percent were obese and typically more difficult to obtain high-quality imaging.
Kinetic modeling is important to understand how to obtain the best quantitative measurement of novel tracers in the organ of interest.
In a lecture at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, Matthew F. Covington, M.D., discussed key findings from recent studies that emphasize the possible prognostic role of positron emission tomography (PET) in de-escalating treatment for breast cancer.
The newly launched Signa PET/MR Air device offers technological features that may bolster image quality and enhance diagnostic accuracy for diseases such as prostate cancer and Alzheimer’s disease.
The new portable ultrasound device, which is being showcased at the American Society of Echocardiography (ASE) conference, offers enhanced cardiac imaging as well as shared transducer interoperability and workflows with existing EPIQ CVx and Affiniti CVx ultrasound systems.
In multiple mammography datasets with the original radiologist-detected abnormality removed, deep learning detection of breast cancer had an average area under the curve (AUC) of 87 percent and an accuracy rate of 83 percent, according to research presented at the recent Society for Imaging Informatics in Medicine (SIIM) conference.
Catch up on the top radiology content of the past week.
In a recent video interview from the Society for Imaging Informatics in Medicine (SIIM) conference, Ali Tejani, M.D., discussed pertinent insights on leveraging the value of adjunctive artificial intelligence (AI)-enabled triage software for computed tomography (CT) scans with radiology workflow improvements to achieve “clinically meaningful change” for patients with incidental pulmonary emboli findings.
In a recent video interview, Stephen Rose, M.D., reviewed a variety of factors that can impact interpretation of breast imaging for women with breast implants and discussed recent research showing a 22 percent reduction in cancer detection rate for this population in comparison to women without breast implants.
For patients initially diagnosed with non-metastatic, castration-resistant prostate cancer, pelvic lymph node involvement and five or more polymetastases detected with prostate-specific membrane antigen (PSMA)/ positron emission tomography (PET) are significantly associated with lower overall survival rates, according to recently presented research at the American Society of Clinical Oncology (ASCO) conference.
FIRMM-pix, a brain magnetic resonance imaging (MRI) software module recently launched at the International Society for Magnetic Resonance in Medicine (ISMRM) conference, reportedly employs visual biofeedback and gamification that coaches patients to stay still during brain MRI exams.
For patients with residual or recurrent grade 2 isocitrate dehydrogenase (IDH)-mutant gliomas, magnetic resonance imaging (MRI) revealed that daily dosing of vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes, led to a median progression-free survival of 27.7 months in comparison to 11.1 months in a placebo group, according to new research presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The combination of Philips’ MR 7700 multi-nuclei scanner with the FDA-approved Xenoview hyperpolarized Xenon magnetic resonance imaging (MRI) contrast agent may facilitate earlier diagnosis and intervention for patients with obstructive lung diseases.
Adjunctive use of an artificial intelligence (AI) software demonstrated nearly equivalent sensitivity and over 28 percent higher accuracy in comparison to radiologist assessment of breast ultrasound images for breast lesions, according to new research presented at the recent Society of Breast Imaging (SBI) conference.
In a recent lecture at the American Roentgen Ray Society (ARRS) 2023 Annual Meeting, Andrew Callen, M.D., discussed a variety of imaging features associated with cerebrospinal fluid (CSF) leaks, the diagnostic utility of the Bern score as well as the merits of 3D T2FS MRI and dynamic computed tomography myelography.
Earlier initiation of imaging after contrast administration with contrast-enhanced mammography may provide better visibility of lesions and conspicuity against background parenchymal enhancement, according to new research presented at the American Roentgen Ray Society (ARRS) 2023 Annual Meeting in Honolulu, Hawaii.
Given the increasing prevalence of breast reconstruction, researchers discussed key signs of common complications on magnetic resonance imaging (MRI), ultrasound and other imaging during a recent presentation at the American Roentgen Ray Society (ARRS) 2023 Annual Meeting in Honolulu, Hawaii.
Three-dimensional (3D) slice-to-volume (SVR) fetal magnetic resonance imaging (MRI) has over six times the fetal optic pathway visualization rate of standard two-dimensional MRI, according to new research presented at the American Roentgen Ray Society (ARRS) 2023 Annual Meeting in Honolulu, Hawaii.
In a recent video interview, Kathy Schilling, M.D., discussed findings from a study of ProFound AI, an adjunctive artificial intelligence (AI) software for digital breast tomosynthesis (DBT), that demonstrated a 23 percent increase in breast cancer detection in comparison to DBT alone.
Comparing year-long findings with and without adjunctive artificial intelligence (AI) at a breast cancer screening program in Spain, researchers found the combination of digital breast tomosynthesis and AI had a 92.5 percent accuracy for diagnosing cancer in patients with elevated risk.
